|
|
Post by brotherm1 on May 22, 2020 21:45:18 GMT -5
$38.7M cash end of March, with $15M restricted leaves $23.7M unencumbered end of March. MNKD burned $11.1M cash Q1 by being ultra conservative with spending and having very good Afrezza sales revenues - due to patients stocking up due to COVID circumstances. Sales have since dropped this quarter so far. Being optimistic I’ll say cash burn now is around $4M per month and thus at the end of this month available cash will be max of $16M.
Seems to me it’s safe to assume - according to Mr. Castagna - MNKD will receive $12.5 million this quarter from UTHR milestone. Should it be received by the end of June, available cash could be around $24.5M June 30. Throw in the $5M CARES act loan MNKD received if you’d like (I’m not betting they won’t return it).
Looks like possibly enough cash to burn through December should MNKD remain ultra conservative with spending, especially if they receive the final $12.5M from UTHR prior to the end if this year.
Though running on cash fumes months close to the end of the year would of course not be at all wise.
MNKD will certainly need much more funds in the years ahead of profitability. And it appears to me MNKD will need additional funding this year to stay in operation. When will they be eligible for the $25M tranche 3 from Midcap? I’m wondering if it’s even worth taking it as it will essentially only be $20M due to the extra $5M that will be restricted with it and the entire amount with interest will need repaid monthly in 36 mos starting 15 mos from now (about $2.5M or more per quarter) and then we will need to maintain Afrezza net sales in line with the Midcap monthly test amounts in order not to be in default. Personally I’d like to see dilution if the share price and volume would increase a bit. Chances the economy will be in good shape for an equity raise a bit later from now, or for taking on more debt this year and the next doesn’t look at all good to me.
Regardless, does anyone know when MNKD will be eligible for the Midcap 3rd tranche?
|
|
|
|
Post by sweedee79 on May 23, 2020 0:44:37 GMT -5
Thanks Brotherm.. this is what I'm paying attention too.. and what has happened historically with this company in the past few years..
I along with a few others sees another pump.. more dilution and warrants.. unless there is some pretty amazing news just around the corner which we all like to convince ourselves of.. and I suppose is possible.. but I doubt it.. we are going to need money from someplace.. I'm not buying anymore shares right now.. In fact have been waiting for an opportunity to sell and this just might be it.. may buy back in later..
|
|
|
|
Post by cjm18 on May 23, 2020 9:08:19 GMT -5
So...dilution is coming in the next 9 to 15 months but we don’t know when. And mnkd isn’t profitable. And that is bad.
Sounds like time to sell If on a short investment horizon. Otherwise nothing has changed. Actually things are looking better than in the past. Most biotechs don’t make money.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 23, 2020 9:21:48 GMT -5
$38.7M cash end of March, with $15M restricted leaves $23.7M unencumbered end of March. MNKD burned $11.1M cash Q1 by being ultra conservative with spending and having very good Afrezza sales revenues - due to patients stocking up due to COVID circumstances. Sales have since dropped this quarter so far. Being optimistic I’ll say cash burn now is around $4M per month and thus at the end of this month available cash will be max of $16M. Seems to me it’s safe to assume - according to Mr. Castagna - MNKD will receive $12.5 million this quarter from UTHR milestone. Should it be received by the end of June, available cash could be around $24.5M June 30. Throw in the $5M CARES act loan MNKD received if you’d like (I’m not betting they won’t return it). Looks like possibly enough cash to burn through December should MNKD remain ultra conservative with spending, especially if they receive the final $12.5M from UTHR prior to the end if this year. Though running on cash fumes months close to the end of the year would of course not be at all wise. MNKD will certainly need much more funds in the years ahead of profitability. And it appears to me MNKD will need additional funding this year to stay in operation. When will they be eligible for the $25M tranche 3 from Midcap? I’m wondering if it’s even worth taking it as it will essentially only be $20M due to the extra $5M that will be restricted with it and the entire amount with interest will need repaid monthly in 36 mos starting 15 mos from now (about $2.5M or more per quarter) and then we will need to maintain Afrezza net sales in line with the Midcap monthly test amounts in order not to be in default. Personally I’d like to see dilution if the share price and volume would increase a bit. Chances the economy will be in good shape for an equity raise a bit later from now, or for taking on more debt this year and the next doesn’t look at all good to me. Regardless, does anyone know when MNKD will be eligible for the Midcap 3rd tranche? That's a very good analysis but I don't see the $11M for the June warrants. So if nothing else comes in for the year that's $36M plus the $38.7M which gives them ~$75M which will take them into 3Q21 so I don't see the need to panic right now. If you add in the $25M from Mid Cap you get MNKD into 2022 and by then TreT Royalties and Pediatric Revenues will start. I'm also expecting an Equity Partnership that will bring in money for the Pediatric Trial and Type 2 Marketing. Also I'm expecting an amended deal with UTHR since they have decided to allow MNKD to be their CMO....that will bring in more money and revenue for MNKD. I can see why Mike is confident about MNKD's future. |
|
|
|
Post by matt on May 23, 2020 9:39:24 GMT -5
There is an old saying in the biotech world - "Raise cash when you can, not when you need it". The world is unpredictable and when something unpredictable happens the financial markets can close up on small companies before they can react. COVID-19 is but one example, the explosion of the "dot com" bubble and the housing crisis of 2008 were others. Would a second wave of COVID infection, perhaps from an even more virulent strain of the disease, cause the financial markets to react even more negatively? That is not a bet a prudent management team wants to make because with a company with an on-going cash burn that is literally a life or death decision; a wrong guess about events totally outside the control of the company can lead to bankruptcy court.
So yes, the company will need more money. You can model all the scenarios you like with UTHR and the SBA loan to determine timing, but the need for cash will become more visible in the coming months. MNKD was a bit coy in the way they worded the disclosure that they did not take the second tranche of Midcap money, but the 10Q disclosure is more precise:
"$10.0 million was available to the Company until April 15, 2020, provided that the Company had achieved Afrezza net revenue of at least $30.0 million on a trailing twelve month basis by that date (which was not achieved)" [emphasis added]
The dual conditions for the third tranche, which is only available until June, 2021, are tied to hitting the UTHR milestones and increased Afrezza net revenue. If the company missed on the $30 million Afrezza net revenue target for the second tranche, it is unlikely they will satisfy the $46.25 million Afrezza net revenue requirement for the third tranche. Even if the company meets the UTHR milestones, they will likely miss the Afrezza net revenue target which means there will be no third tranche available under the terms of the current facility. That implies the need for a cash raise sooner rather than later.
Most biotechs find it extremely hard to raise money during the summer months even in a normal year which is why there are so many investor financial conferences held in September and October. That seems the most likely time for the next raise, although it could come sooner.
|
|
|
|
Post by peppy on May 23, 2020 10:00:20 GMT -5
There is an old saying in the biotech world - "Raise cash when you can, not when you need it". The world is unpredictable and when something unpredictable happens the financial markets can close up on small companies before they can react. COVID-19 is but one example, the explosion of the "dot com" bubble and the housing crisis of 2008 were others. Would a second wave of COVID infection, perhaps from an even more virulent strain of the disease, cause the financial markets to react even more negatively? That is not a bet a prudent management team wants to make because with a company with an on-going cash burn that is literally a life or death decision; a wrong guess about events totally outside the control of the company can lead to bankruptcy court. So yes, the company will need more money. You can model all the scenarios you like with UTHR and the SBA loan to determine timing, but the need for cash will become more visible in the coming months. MNKD was a bit coy in the way they worded the disclosure that they did not take the second tranche of Midcap money, but the 10Q disclosure is more precise: "$10.0 million was available to the Company until April 15, 2020, provided that the Company had achieved Afrezza net revenue of at least $30.0 million on a trailing twelve month basis by that date ( which was not achieved)" [emphasis added] The dual conditions for the third tranche, which is only available until June, 2021, are tied to hitting the UTHR milestones and increased Afrezza net revenue. If the company missed on the $30 million Afrezza net revenue target for the second tranche, it is unlikely they will satisfy the $46.25 million Afrezza net revenue requirement for the third tranche. Even if the company meets the UTHR milestones, they will likely miss the Afrezza net revenue target which means there will be no third tranche available under the terms of the current facility. That implies the need for a cash raise sooner rather than later. Most biotechs find it extremely hard to raise money during the summer months even in a normal year which is why there are so many investor financial conferences held in September and October. That seems the most likely time for the next raise, although it could come sooner. Aged said, the Afrezza net revenue met? or third tranche requirements... All? agedhippie ? Am I confused once again? Here it is, "Ok - that's weird. The tranche 3 requirement was revised, but the tranche 2 requirement wasn't. It looks to me like StockTwits was right (not something I often say). In other words it wasn't Mike's decision because they missed the revenue target so the option wasn't there. At the moment they are comfortably on target for Tranche 3 (about $2.5M over today by my estimate)." somewhere in this thread mnkd.proboards.com/thread/11994/annual-shareholders?page=8 |
|
|
|
Post by morfu on May 23, 2020 10:03:15 GMT -5
$38.7M cash end of March, with $15M restricted leaves $23.7M unencumbered end of March. MNKD burned $11.1M cash Q1 by being ultra conservative with spending and having very good Afrezza sales revenues - due to patients stocking up due to COVID circumstances. Sales have since dropped this quarter so far. Being optimistic I’ll say cash burn now is around $4M per month and thus at the end of this month available cash will be max of $16M. Seems to me it’s safe to assume - according to Mr. Castagna - MNKD will receive $12.5 million this quarter from UTHR milestone. Should it be received by the end of June, available cash could be around $24.5M June 30. Throw in the $5M CARES act loan MNKD received if you’d like (I’m not betting they won’t return it). Looks like possibly enough cash to burn through December should MNKD remain ultra conservative with spending, especially if they receive the final $12.5M from UTHR prior to the end if this year. Though running on cash fumes months close to the end of the year would of course not be at all wise. MNKD will certainly need much more funds in the years ahead of profitability. And it appears to me MNKD will need additional funding this year to stay in operation. When will they be eligible for the $25M tranche 3 from Midcap? I’m wondering if it’s even worth taking it as it will essentially only be $20M due to the extra $5M that will be restricted with it and the entire amount with interest will need repaid monthly in 36 mos starting 15 mos from now (about $2.5M or more per quarter) and then we will need to maintain Afrezza net sales in line with the Midcap monthly test amounts in order not to be in default. Personally I’d like to see dilution if the share price and volume would increase a bit. Chances the economy will be in good shape for an equity raise a bit later from now, or for taking on more debt this year and the next doesn’t look at all good to me. Regardless, does anyone know when MNKD will be eligible for the Midcap 3rd tranche? That's a very good analysis but I don't see the $11M for the June warrants. So if nothing else comes in for the year that's $36M plus the $38.7M which gives them ~$75M which will take them into 3Q21 so I don't see the need to panic right now. If you add in the $25M from Mid Cap you get MNKD into 2022 and by then TreT Royalties and Pediatric Revenues will start. I'm also expecting an Equity Partnership that will bring in money for the Pediatric Trial and Type 2 Marketing. Also I'm expecting an amended deal with UTHR since they have decided to allow MNKD to be their CMO....that will bring in more money and revenue for MNKD. I can see why Mike is confident about MNKD's future. What is also missing is the fact, that the Afrezza revenue shows a trend over the last years. If that trend would continue (it was week over the last weeks), the cash lasted a lot longer. |
|
|
|
Post by MnkdWASmyRtrmntPlan on May 23, 2020 11:21:09 GMT -5
Yeah Brother, that is the cold reality. And Sweedee, I will not be a buyer anytime soon (ok, I don't have the funds right now). But, I also won't be a seller.
I pay attention to Mike's words that MNKD is a good buy right now. I still remember Obama calling the stock market bottom in the 2008/2009 downturn when he said that now is a good time to buy. With his advisors, he had keen insight to the broad market and that ended up being a darn good call he made. Likewise, Mike has possibly the best insight to MNKD's future potential, probably better than anyone else, so I think that call of his deserves to be noted. Sure, Mike always tries to talk things up in his conference calls, but I don't recall him ever really making a call that blatant in the past, other than his quickly deleted tweet that it is all up from here.
There are a lot of factors that we do not have vision into. Although I don't have much faith that MNKD will be able to pull off a Remdesivir or other Covid boon, that is a possibility and that could potentially be a jackpot in terms of future income and also in turning "Mannkind" into a household word (great advertising). Dr. Kendall's papers will start being released, along with other potential developments at the "Virtual" ADA 2020 (June 12-16). Sales will continue to improve from Vdex clinics. The fact that MNKD is getting closer to breakeven, so new financing that may be required will be more readily available and on better terms. Clinical trial results coming up. Bluehale launches coming up. Debt reduction. Pipeline … who knows. Someday, RLS will happen. And of course, Peds continues to get closer. As others have pointed out, there may not be any need for additional dilution or financing.
I see more potential upside than down. I just wish Mike and the board would start buying some shares. Three-hundred-K (buck and a half) shares is nothing for a CEO or any directors. If they started to buy shares now, this stock would fly, shorts would scramble and SP will hit the clouds. Someday, that will happen, and I am not selling til it does.
|
|
|
|
Post by morfu on May 23, 2020 11:34:37 GMT -5
Yeah Brother, that is the cold reality. And Sweedee, I will not be a buyer anytime soon (ok, I don't have the funds right now). But, I also won't be a seller. I pay attention to Mike's words that MNKD is a good buy right now. I still remember Obama calling the stock market bottom in the 2008/2009 downturn when he said that now is a good time to buy. With his advisors, he had keen insight to the broad market and that ended up being a darn good call he made. Likewise, Mike has possibly the best insight to MNKD's future potential, probably better than anyone else, so I think that call of his deserves to be noted. Sure, Mike always tries to talk things up in his conference calls, but I don't recall him ever really making a call that blatant in the past, other than his quickly deleted tweet that it is all up from here. There are a lot of factors that we do not have vision into. Although I don't have much faith that MNKD will be able to pull off a Remdesivir or other Covid boon, that is a possibility and that could potentially be a jackpot in terms of future income and also in turning "Mannkind" into a household word (great advertising). Dr. Kendall's papers will start being released, along with other potential developments at the "Virtual" ADA 2020 (June 12-16). Sales will continue to improve from Vdex clinics. The fact that MNKD is getting closer to breakeven, so new financing that may be required will be more readily available and on better terms. Clinical trial results coming up. Bluehale launches coming up. Debt reduction. Pipeline … who knows. Someday, RLS will happen. And of course, Peds continues to get closer. As others have pointed out, there may not be any need for additional dilution or financing. I see more potential upside than down. I just wish Mike and the board would start buying some shares. Three-hundred-K (buck and a half) shares is nothing for a CEO or any directors. If they started to buy shares now, this stock would fly, shorts would scramble and SP will hit the clouds. Someday, that will happen, and I am not selling til it does. Well.. I am following the "not one share!" idea!!! I am happy with the shares I have and see no point selling any of them right now, because I dont think this is a fair value for this stock even including the risk. However, if this company survives and becomes profitable, I see even less reason to sell any share.. I know of no other company which has this solid revenue trend and I dont see it slowing down any time soon!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 23, 2020 11:48:06 GMT -5
Yeah Brother, that is the cold reality. And Sweedee, I will not be a buyer anytime soon (ok, I don't have the funds right now). But, I also won't be a seller. I pay attention to Mike's words that MNKD is a good buy right now. I still remember Obama calling the stock market bottom in the 2008/2009 downturn when he said that now is a good time to buy. With his advisors, he had keen insight to the broad market and that ended up being a darn good call he made. Likewise, Mike has possibly the best insight to MNKD's future potential, probably better than anyone else, so I think that call of his deserves to be noted. Sure, Mike always tries to talk things up in his conference calls, but I don't recall him ever really making a call that blatant in the past, other than his quickly deleted tweet that it is all up from here. There are a lot of factors that we do not have vision into. Although I don't have much faith that MNKD will be able to pull off a Remdesivir or other Covid boon, that is a possibility and that could potentially be a jackpot in terms of future income and also in turning "Mannkind" into a household word (great advertising). Dr. Kendall's papers will start being released, along with other potential developments at the "Virtual" ADA 2020 (June 12-16). Sales will continue to improve from Vdex clinics. The fact that MNKD is getting closer to breakeven, so new financing that may be required will be more readily available and on better terms. Clinical trial results coming up. Bluehale launches coming up. Debt reduction. Pipeline … who knows. Someday, RLS will happen. And of course, Peds continues to get closer. As others have pointed out, there may not be any need for additional dilution or financing. I see more potential upside than down. I just wish Mike and the board would start buying some shares. Three-hundred-K (buck and a half) shares is nothing for a CEO or any directors. If they started to buy shares now, this stock would fly, shorts would scramble and SP will hit the clouds. Someday, that will happen, and I am not selling til it does. Too bad you don't have funds to BUY....You gave a good case. COVID is a red herring. I'm not expecting anything. We are definitely closer to the bottom than the top so everyone should be LOCKED AND LOADED and ready to ride this thing HIGHER. The turnaround is complete and it's time for Mike to execute his strategy. I don't mind another dilution if the SP is much higher and less shares have to be used. As long as they are investing in the business and not raising cash to keep the lights on. Capital Equipment is not an issue right now since they are running 1 shift and only 3 Lines (I believe). When they start hiring more employees for a 2nd & 3rd shift and building more lines...then they can dilute to buy equipment. UTHR will fork over money to expand TreT prior to approval. MNKD has weathered the storm and the SUN is RISING!!!! Expecting more UPGRADES and NEW COVERAGE. Expect Mike to climb up the tier of investment conferences after the summer. They are done with the lower tier (but very helpful) players. It's time for MNKD to play with the Medium Players. The BIG BOYS are a ways off. When MNKD hits the 10 figure revenue mark then GS will be calling. Also keep in mind as the months progress MNKD does not have to dilute with equity. They should be able to enter the Debt Markets and raise friendlier debt. We shall see!! |
|
|
|
Post by mytakeonit on May 23, 2020 15:39:43 GMT -5
You can buy now ... or cry later. I definitely have been buying and I'm not worried. I believe everything is on track.
But, that's mytakeonit
|
|
|
|
Post by cretin11 on May 23, 2020 18:30:18 GMT -5
$38.7M cash end of March, with $15M restricted leaves $23.7M unencumbered end of March. MNKD burned $11.1M cash Q1 by being ultra conservative with spending and having very good Afrezza sales revenues - due to patients stocking up due to COVID circumstances. Sales have since dropped this quarter so far. Being optimistic I’ll say cash burn now is around $4M per month and thus at the end of this month available cash will be max of $16M. Seems to me it’s safe to assume - according to Mr. Castagna - MNKD will receive $12.5 million this quarter from UTHR milestone. Should it be received by the end of June, available cash could be around $24.5M June 30. Throw in the $5M CARES act loan MNKD received if you’d like (I’m not betting they won’t return it). Looks like possibly enough cash to burn through December should MNKD remain ultra conservative with spending, especially if they receive the final $12.5M from UTHR prior to the end if this year. Though running on cash fumes months close to the end of the year would of course not be at all wise. MNKD will certainly need much more funds in the years ahead of profitability. And it appears to me MNKD will need additional funding this year to stay in operation. When will they be eligible for the $25M tranche 3 from Midcap? I’m wondering if it’s even worth taking it as it will essentially only be $20M due to the extra $5M that will be restricted with it and the entire amount with interest will need repaid monthly in 36 mos starting 15 mos from now (about $2.5M or more per quarter) and then we will need to maintain Afrezza net sales in line with the Midcap monthly test amounts in order not to be in default. Personally I’d like to see dilution if the share price and volume would increase a bit. Chances the economy will be in good shape for an equity raise a bit later from now, or for taking on more debt this year and the next doesn’t look at all good to me. Regardless, does anyone know when MNKD will be eligible for the Midcap 3rd tranche? That's a very good analysis but I don't see the $11M for the June warrants. So if nothing else comes in for the year that's $36M plus the $38.7M which gives them ~$75M which will take them into 3Q21 so I don't see the need to panic right now. If you add in the $25M from Mid Cap you get MNKD into 2022 and by then TreT Royalties and Pediatric Revenues will start. I'm also expecting an Equity Partnership that will bring in money for the Pediatric Trial and Type 2 Marketing. Also I'm expecting an amended deal with UTHR since they have decided to allow MNKD to be their CMO....that will bring in more money and revenue for MNKD. I can see why Mike is confident about MNKD's future. Casper what do you mean by Equity Partnership that will bring in money for the pediatric trial? Is there some news or rumor about this? I’ve missed it if so, but would seem to be significant. |
|
|
|
Post by agedhippie on May 23, 2020 19:16:59 GMT -5
... I don't mind another dilution if the SP is much higher and less shares have to be used. As long as they are investing in the business and not raising cash to keep the lights on. Capital Equipment is not an issue right now since they are running 1 shift and only 3 Lines (I believe). When they start hiring more employees for a 2nd & 3rd shift and building more lines...then they can dilute to buy equipment. UTHR will fork over money to expand TreT prior to approval. MNKD has weathered the storm and the SUN is RISING!!!! Expecting more UPGRADES and NEW COVERAGE. Expect Mike to climb up the tier of investment conferences after the summer. They are done with the lower tier (but very helpful) players. It's time for MNKD to play with the Medium Players. The BIG BOYS are a ways off. When MNKD hits the 10 figure revenue mark then GS will be calling. Also keep in mind as the months progress MNKD does not have to dilute with equity. They should be able to enter the Debt Markets and raise friendlier debt. We shall see!! Lets sort through a few things here: I don't mind another dilution if the SP is much higher and less shares have to be used. As long as they are investing in the business and not raising cash to keep the lights on.That begs the question; are you not OK with them diluting to keep the lights on? I suspect the answer is actually you are, and when it happens you will say it's sad but they had no choice. Capital Equipment is not an issue right now since they are running 1 shift and only 3 Lines (I believe).I didn't think they were currently running all the lines. I thought it was a single line and the others were mothballed although one was upgraded to make TreT, but I am not sure. Does anyone have the answer to that? UTHR will fork over money to expand TreT prior to approval. Not without lowering the royalties. It would be treated as a pre-payment. MNKD has weathered the storm and the SUN is RISING!!!! [etc.]Things are nowhere near that point. The company is a micro-cap and is not going to get out of the lower end of the small-caps any time soon at best. That's not a good place to be (although better than being a micro-cap as now). Also keep in mind as the months progress MNKD does not have to dilute with equity. They should be able to enter the Debt Markets and raise friendlier debt.Lol. You realize that the next step up the funder ladder is Deerfield's tier (that's why Mannkind was originally involved with Deerfield, Mannkind were a $2BN company at the time that loan was made). Add to that MidCap has first claim on the assets to the debt would be unsecured and I think your chances of friendlier debt are zero. We shall see!!Indeed we shall  But I am curious. What are the time lines you see on this? |
|
|
|
Post by akemp3000 on May 23, 2020 19:29:35 GMT -5
While it's true that the UTHR Tre-T revenues, pediatric approval and international sales are off in the distance, it's also true that the market reacts to news in advance of impending events. IMO, it's hard to imagine such approvals occurring in the latter half of 2020 without being reflected in the stock price. We'll know soon enough. GLTA
|
|
|
|
Post by cretin11 on May 23, 2020 21:09:46 GMT -5
Yeah Brother, that is the cold reality. And Sweedee, I will not be a buyer anytime soon (ok, I don't have the funds right now). But, I also won't be a seller. I pay attention to Mike's words that MNKD is a good buy right now. I still remember Obama calling the stock market bottom in the 2008/2009 downturn when he said that now is a good time to buy. With his advisors, he had keen insight to the broad market and that ended up being a darn good call he made. Likewise, Mike has possibly the best insight to MNKD's future potential, probably better than anyone else, so I think that call of his deserves to be noted. Sure, Mike always tries to talk things up in his conference calls, but I don't recall him ever really making a call that blatant in the past, other than his quickly deleted tweet that it is all up from here. There are a lot of factors that we do not have vision into. Although I don't have much faith that MNKD will be able to pull off a Remdesivir or other Covid boon, that is a possibility and that could potentially be a jackpot in terms of future income and also in turning "Mannkind" into a household word (great advertising). Dr. Kendall's papers will start being released, along with other potential developments at the "Virtual" ADA 2020 (June 12-16). Sales will continue to improve from Vdex clinics. The fact that MNKD is getting closer to breakeven, so new financing that may be required will be more readily available and on better terms. Clinical trial results coming up. Bluehale launches coming up. Debt reduction. Pipeline … who knows. Someday, RLS will happen. And of course, Peds continues to get closer. As others have pointed out, there may not be any need for additional dilution or financing. I see more potential upside than down. I just wish Mike and the board would start buying some shares. Three-hundred-K (buck and a half) shares is nothing for a CEO or any directors. If they started to buy shares now, this stock would fly, shorts would scramble and SP will hit the clouds. Someday, that will happen, and I am not selling til it does. Well.. I am following the "not one share!" idea!!! I am happy with the shares I have and see no point selling any of them right now, because I dont think this is a fair value for this stock even including the risk. However, if this company survives and becomes profitable, I see even less reason to sell any share.. I know of no other company which has this solid revenue trend and I dont see it slowing down any time soon!
No other company which has this solid revenue trend? I must be missing something here. |
|
But I am curious. What are the time lines you see on this?